Well ahead of its 19 May 2015 Prescription Drug User Fee Act action date, Amgen’s bispecific T-cell engager (BiTE) antibody Blincyto (blinatumomab) won the FDA’s blessing on 3 December to enter the US market as a treatment for Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow, which has a median overall survival of just 3-5 months.
Blinatumomab, which is the first of the BiTE antibodies, is designed to direct the body's cell-destroying T-cells against target cells...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
